These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32422324)

  • 1. Orexin and Parkinson's disease: A protective neuropeptide with therapeutic potential.
    Liu C; Xue Y; Liu MF; Wang Y; Chen L
    Neurochem Int; 2020 Sep; 138():104754. PubMed ID: 32422324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orexin pathway in Parkinson's disease: a review.
    Alrouji M; Al-Kuraishy HM; Al-Gareeb AI; Zaafar D; Batiha GE
    Mol Biol Rep; 2023 Jul; 50(7):6107-6120. PubMed ID: 37155018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the Role of Orexinergic Neurons in Parkinson's Disease.
    Kumar S; Behl T; Sehgal A; Singh S; Sharma N; Bhatia S; Al-Harassi A; Abdel-Daim MM; Bungau S
    Neurotox Res; 2021 Dec; 39(6):2141-2153. PubMed ID: 34495449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orexinergic neurons are involved in the chemosensory control of breathing during the dark phase in a Parkinson's disease model.
    Oliveira LM; Falquetto B; Moreira TS; Takakura AC
    Exp Neurol; 2018 Nov; 309():107-118. PubMed ID: 30110606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sparing of orexin-A and orexin-B neurons in the hypothalamus and of orexin fibers in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated macaques.
    Bensaid M; Tandé D; Fabre V; Michel PP; Hirsch EC; François C
    Eur J Neurosci; 2015 Jan; 41(1):129-36. PubMed ID: 25328140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orexin and Sleep Disturbances in Alpha-Synucleinopathies: a Systematic Review.
    Raheel K; See QR; Munday V; Fakhroo B; Ivanenko O; Salvatelli ML; Mutti C; Goadsby PJ; Delogu A; Naismith SL; Holland P; Parrino L; Chaudhuri KR; Rosenzweig I
    Curr Neurol Neurosci Rep; 2024 Sep; 24(9):389-412. PubMed ID: 39031323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and chemogenetic orexin/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson's disease.
    Stanojlovic M; Pallais JP; Lee MK; Kotz CM
    Mol Brain; 2019 Oct; 12(1):87. PubMed ID: 31666100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demystifying the Neuroprotective Role of Neuropeptides in Parkinson's Disease: A Newfangled and Eloquent Therapeutic Perspective.
    Behl T; Madaan P; Sehgal A; Singh S; Makeen HA; Albratty M; Alhazmi HA; Meraya AM; Bungau S
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depletion of hypothalamic hypocretin/orexin neurons correlates with impaired memory in a Parkinson's disease animal model.
    Oliveira LM; Henrique E; Bustelli IB; Netto NFC; Moreira TS; Takakura AC; Caetano AL
    Exp Neurol; 2020 Jan; 323():113110. PubMed ID: 31712126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Several neuropeptides involved in parkinsonian neuroprotection modulate the firing properties of nigral dopaminergic neurons.
    Chen L; Liu C; Xue Y; Chen XY
    Neuropeptides; 2023 Jun; 99():102337. PubMed ID: 37087783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of orexin in Parkinson's disease.
    Braun A; Manavis J; Yamanaka A; Ootsuka Y; Blumbergs P; Bobrovskaya L
    J Neurosci Res; 2024 Mar; 102(3):e25322. PubMed ID: 38520160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased plasma orexin-A concentrations are associated with the non-motor symptoms in Parkinson's disease patients.
    Huang S; Zhao Z; Ma J; Hu S; Li L; Wang Z; Sun W; Shi X; Li M; Zheng J
    Neurosci Lett; 2021 Jan; 741():135480. PubMed ID: 33161104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypocretin (orexin) loss in Parkinson's disease.
    Fronczek R; Overeem S; Lee SY; Hegeman IM; van Pelt J; van Duinen SG; Lammers GJ; Swaab DF
    Brain; 2007 Jun; 130(Pt 6):1577-85. PubMed ID: 17470494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson's Disease.
    Liu MF; Xue Y; Liu C; Liu YH; Diao HL; Wang Y; Pan YP; Chen L
    Front Neurosci; 2018; 12():835. PubMed ID: 30524223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Sociability and Social Memory Impairment in the A53T Mouse Model of Parkinson's Disease Are Ameliorated by Chemogenetic Modulation of Orexin Neuron Activity.
    Stanojlovic M; Pallais Yllescas JP; Vijayakumar A; Kotz C
    Mol Neurobiol; 2019 Dec; 56(12):8435-8450. PubMed ID: 31250383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the role of Orexin-A neuropeptide in Parkinson's disease: A systematic review and meta-analysis.
    Suresh V; Bardhan M; Ghosh S; Chandani Y; Satapathy P; Roy P; Shamim MA; Gandhi AP; Sandeep M; Rustagi S; Sah R; Padhi BK
    Clin Neurol Neurosurg; 2024 Jul; 242():108320. PubMed ID: 38781804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Orexinergic (Hypocretin) System and Nociception: An Update to Supraspinal Mechanisms.
    Roohbakhsh A; Alavi MS; Azhdari-Zarmehri H
    Curr Med Chem; 2018; 25(32):3917-3929. PubMed ID: 28552056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orexins increase the firing activity of nigral dopaminergic neurons and participate in motor control in rats.
    Liu C; Xue Y; Liu MF; Wang Y; Liu ZR; Diao HL; Chen L
    J Neurochem; 2018 Nov; 147(3):380-394. PubMed ID: 30102759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The sleep-wake cycle, the hypocretin/orexin system and narcolepsy: advances from preclinical research to treatment.
    Arias-Carrión O; Bradbury M
    CNS Neurol Disord Drug Targets; 2009 Aug; 8(4):232-4. PubMed ID: 19689304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson's disease: A retrospective study.
    Ogawa T; Kajiyama Y; Ishido H; Chiba S; Revankar GS; Nakano T; Taniguchi S; Kanbayashi T; Ikenaka K; Mochizuki H
    PLoS One; 2022; 17(12):e0279747. PubMed ID: 36584130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.